Novel glutamatergic drugs for the treatment of mood disorders
Kyle AB Lapidus, Laili Soleimani, James W MurroughMood and Anxiety Disorders Program, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USAAbstract: Mood disorders are common and debilitating, resulting in a significant ...
Murrough JW, Lapidus KAB, Soleimani L
doaj
A comparative exploration of monoamine neurotransmitter transport disorders: mechanisms, clinical manifestations, and therapeutic approaches. [PDF]
Al Sari RR+9 more
europepmc +1 more source
Utilization of Medicinal Plants in Mental Disorders: Neuroplasticity and Neuroprotection in Biomodels. [PDF]
Estela-Zape JL+3 more
europepmc +1 more source
Disturbance of neurotransmitter metabolites in peripheral blood of schizophrenia patients treated with olanzapine: a preliminary targeted metabolomic study. [PDF]
Yin J, Gan Y, Jiang C, Wang J, Zhou Z.
europepmc +1 more source
The neurochemical basis of photic entrainment of the circadian pacemaker [PDF]
Circadian rhythmicity in mammals is controlled by the action of a light-entrainable hypothalamus, in association with two cell clusters known as the supra chiasmatic nuclei (SCN).
Buckley, Becky+2 more
core +1 more source
Neuroinflammation-A Crucial Factor in the Pathophysiology of Depression-A Comprehensive Review. [PDF]
Sălcudean A+13 more
europepmc +1 more source
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation. [PDF]
Krasner H, Ong CV, Hewitt P, Vida TA.
europepmc +1 more source
Immune Dysregulation in Depression and Anxiety: A Review of the Immune Response in Disease and Treatment. [PDF]
Hole C, Dhamsania A, Brown C, Ryznar R.
europepmc +1 more source